Skip to main content
Lung cancer metastasis-National Cancer Institute \ Winship Cancer Institute of Emory University

Host-Tumor Interactions Research Program

Tumor growth, invasion, and metastasis depend not only on the tumor cell alone, but also on the complex interactions between the tumor cells and their host. The goal of the Host-Tumor Interactions Research Program is to develop a detailed and mechanistic understanding of not just the tumor cell and tumor mutations, but also all the components of the host microenvironment that influence cancer and the response to cancer therapy.

RESEARCH THEMES

With the goal of understanding how complex interactions between tumor cells and their host contribute to cancer, the Host-Tumor Interactions program focuses on four specific research themes:

Understanding how new blood vessels form to feed tumors – and finding ways to block these processes

Identifying molecules involved in communication between tumor cells and their cellular and structural microenvironment

Uncovering how inflammation triggers and promotes cancer

Integrating knowledge about host-tumor interactions to understand how tumors evolve in a changing microenvironment

Meet the Program Members

The Host-Tumor Interactions program is co-led by Mary M. Zutter, M.D., and Jeffrey Rathmell, Ph.D. The basic, translational, and clinical scientists who make up this program are focused on discovering and understanding these interactions, with the ultimate goal of developing strategies to control tumor progression and metastasis by targeting these interactions.


Featured Publications

Program News

December 12, 2019

Richmond receives legacy award from Society for Leukocyte Biology

Ann Richmond, PhD, Ingram Professor of Cancer Research, is the 2019 recipient of the Society for Leukocyte Biology Legacy Award.
November 7, 2019

Project seeks new way to assess immunotherapy effectiveness

GE Healthcare has awarded researchers $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.
October 31, 2019

Rathmell lands award from Lupus Research Alliance

Jeffrey Rathmell, PhD, is a 2019 recipient of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity.